B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis

Haematologica

Volumn 92, Issue 2, 2007, Pages 258-259

  Bogani, Costanza ^a   Guglielmelli, Paola ^a   Antonioli, Elisabetta ^a   Pancrazzi, Alessandro ^a   Bosi, Alberto ^a   Vannucchi, Alessandro Maria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Idiopathic myelofibrosis; JAK2; Myeloproliferative disease; Stem cells

Indexed keywords

JANUS KINASE 2; COMPLEMENTARY DNA;

ARTICLE; B LYMPHOCYTE; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; GENE MUTATION; HUMAN; MYELOID METAPLASIA; NATURAL KILLER CELL; T LYMPHOCYTE; BLOOD; BLOOD CELL COUNT; CYTOLOGY; GENETICS; LETTER; METABOLISM; MUTATION; MYELOFIBROSIS;

B-LYMPHOCYTES; BLOOD CELL COUNT; CELL LINEAGE; DNA, COMPLEMENTARY; HUMANS; JANUS KINASE 2; KILLER CELLS, NATURAL; MUTATION; MYELOFIBROSIS; T-LYMPHOCYTES;

EID: 33947528089     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10527     Document Type: Article

References (10)

1. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005;105:4187-90.
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
3. Kralovics R, Passamonti F, Buser AS, Soon-Siong T, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
4. Lasho TL, Mesa R, Gilliland DG, Tefferi A. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol 2005;130:797-9.
5. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 2006;103:6224-9.
6. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006;108:3128-34.
7. Bellanne-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006;108:346-52.
8. Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006;20:1055-60.
9. Delhommeau F, Dupont S, Tonetti C, Massé A, Godin I, Le Couedic J-P, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lympho-myeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007;109:71-7.
10. Hoffman R, Ravandi-Kashani F. Idiopathic myelofibrosis. In: Hoffman R, Benz EJJ, Shattil SJ, et al., eds. Hematology Basic Principles and Practice. Philadelphia, PA: Elsevier Churcill Livingstone; 2005. p. 1255-76.